Groupe d'Etude en Oncologie du Quebec

Title	Diagnostic Value of Diffusion-weighted Magnetic Resonance Imaging for Detection of Peritoneal Metastases in High-risk Pancreatic Ductal Adenocarcinoma: a Pilot Study.
Protocole ID	2022-6186
ClinicalTrials.gov ID	NCT05340569
Cancer Type(s)	Pancreas
Phase	Other
Stage
Study Type	Diagnostic
Drug
Institution	CHU DE QUEBEC – UNIVERSITE LAVAL HOPITAL DE L'ENFANT-JESUS 1401 18e Rue, Québec, QC, G1J 1Z4
City
Principal Investigator	Dr. Alexandre Brind’Amour
Coordinator
Status	Recruiting
Activation Date	06-04-2022
Eligibility Criteria	Confirmed diagnosis of pancreatic ductal adenocarcinoma. Resectable disease or borderline resectable disease based on CT. Tumor size ≥ 3 cm. CA 19-9 ≥ 400 U/mL with normal bilirubin level (< 40) No evidence of distant metastases. Patient fit for pancreatic resection (ECOG 0 or 1).
Exclusion Criteria	Impossibility to obtain tissue diagnosis preoperatively confirming pancreatic ductal adenocarcinoma. Locally advanced disease on CT. Tumor size < 3 cm. CA 19-9 < 400 U/mL or CA 19-9 ≥ 400 U/mL with no preoperative drainage. Suspicion of distant metastases, including peritoneal metastases, on CT. Patient who is unable to have MRI. Patient unfit for pancreatic resection (ECOG 2 or more).

Groupe d'étude en oncologie du Québec